Florida Senate - 2015                        COMMITTEE AMENDMENT
       Bill No. SB 764
       
       
       
       
       
       
                                Ì1048543Î104854                         
       
                              LEGISLATIVE ACTION                        
                    Senate             .             House              
                  Comm: RCS            .                                
                  03/10/2015           .                                
                                       .                                
                                       .                                
                                       .                                
       —————————————————————————————————————————————————————————————————




       —————————————————————————————————————————————————————————————————
       The Committee on Criminal Justice (Evers) recommended the
       following:
       
    1         Senate Amendment (with title amendment)
    2  
    3         Delete line 292
    4  and insert:
    5         176. Mitragynine or 7-Hydroxymitragynine, except for any
    6  drug product approved by the United States Food and Drug
    7  Administration which contains Mitragynine or 7
    8  Hydroxymitragynine, including any of their isomers, esters,
    9  ethers, salts, and salts of isomers, esters, and ethers, if the
   10  existence of such isomers, esters, ethers, and salts is possible
   11  within the specific chemical designation.
   12  
   13  ================= T I T L E  A M E N D M E N T ================
   14  And the title is amended as follows:
   15         Delete lines 3 - 4
   16  and insert:
   17         893.03, F.S.; scheduling Mitragynine and 7
   18         Hydroxymitragynine, constituents of Kratom, in a
   19         schedule of controlled substances; scheduling isomers,
   20         esters, ethers, salts, and salts of isomers, esters,
   21         and ethers of Mitragynine and 7-Hydroxymitragynine in
   22         a schedule of controlled substances; providing an
   23         exception from scheduling for any drug product
   24         approved by the United States Food and Drug
   25         Administration which contains Mitragynine or 7
   26         Hydroxymitragynine; reenacting ss. 39.01(30)(a) and